Press releaseGlobe Newswire
Cadrenal Therapeutics
CVKD · NASDAQ
$1.04−$0.02 (−1.89%)TodayMarket closed ·
Prev close $1.06
Latest news
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
- Press releaseGlobe Newswire
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
- News
Cadrenal Therapeutics Unveils Cardiac Critical Care Franchise, Seeks Partners For Late-Stage Cardiovascular Assets
- Press releaseGlobe Newswire
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
- Press releaseGlobe Newswire
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
- Press releaseGlobe Newswire
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
- Press releaseGlobe Newswire
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseBusiness Wire
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Press releaseBusiness Wire
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
- Press releaseBusiness Wire
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
- Press releaseBusiness Wire
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
- Press releaseBusiness Wire
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
- Press releaseBusiness Wire
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
- Press releaseBusiness Wire
Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq
- Press releaseBusiness Wire
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
- Press releaseBusiness Wire
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
- Press releaseBusiness Wire
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
- Press releaseBusiness Wire
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
- Press releaseBusiness Wire
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
- Press releaseBusiness Wire
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
- Press releaseBusiness Wire
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
- Press releaseBusiness Wire
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
- Press releasePRNewswire
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook
- Press releasePRNewswire
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
- Press releasePRNewswire
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releasePRNewswire
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
- Press releasePRNewswire
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility
- Press releasePRNewswire
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM
- Press releasePRNewswire
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference
- NewsAvi Kapoor
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
- Press releasePRNewswire
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
- Press releasePRNewswire
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
- Press releasePRNewswire
Cadrenal Therapeutics to Present at Upcoming Investor Conferences
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.